论文部分内容阅读
对２１例骨及软组织恶性肿瘤病人手术前后给予４４次大剂量ＤＤＰ（１００ｍｇ／ｍ２），ＭＴＸ（２００ｍｇ／ｋｇ）化疗。化疗前后分别测定血清尿素（ＵＲＥＡ），血清肌酐（Ｃｒ），血和尿中β２－ＭＧ的含量，结果ＤＤＰ化疗组２０例病人有１４例中β２－ＭＧ含量升高（Ｐ＜０．０５）。作者认为用同位素方法测定尿中β２－ＭＧ值观察接受大剂量ＤＤＰ、ＭＴＸ化疗骨及软组织肿瘤病人的肾功能损害程度，结果稳定可靠。化疗前尿中β２－ＭＧ超过０．２５μｇ／Ｌ以上者应停止大剂量ＤＤＰ、ＭＴＸ化疗
Forty-one patients with malignant bone and soft tissue tumors were given 44 large doses of DDP (100 mg/m2) and MTX (200 mg/kg) chemotherapy before and after surgery. The levels of serum urea (UREA), serum creatinine (Cr), blood and urine β2-MG levels were measured before and after chemotherapy. The results showed that β2-MG levels increased in 14 of 20 patients in the DDP chemotherapy group (P<0.05). . The authors believe that the determination of β2-MG in urine by isotope method was used to observe the degree of renal impairment in patients receiving high-dose DDP, MTX chemotherapy bone and soft tissue tumors. The results were stable and reliable. Patients with β2-MG in excess of 0.25 μg/L in urine before chemotherapy should stop large-dose DDP and MTX chemotherapy